贝雅维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价38美元
eyepoint pharmaceuticals的分析师评级
H.C. Wainwright维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价30美元
eyepoint pharmaceuticals积极前景:DURAVYU的第3阶段LUGANO试验推动买入评级提升
第一资本维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价35美元
Scotiabank开始覆盖eyepoint pharmaceuticals,给予板块表现评级,并宣布目标价为18美元。
瑞穗证券维持EyePoint Pharmaceuticals(EYPT.US)买入评级
eyepoint pharmaceuticals (EYPT) 从瑞穗证券获得买入评级
第一资本维持EyePoint Pharmaceuticals(EYPT.US)买入评级,维持目标价35美元
eyepoint pharmaceuticals 通过 Jefferies 公司宣布股价目标为15.00美元/股
富瑞集团首予EyePoint Pharmaceuticals(EYPT.US)买入评级,目标价15美元
在Duravyu有希望的发展中,eyepoint pharmaceuticals的表现优于市场预期。
eyepoint pharmaceuticals 分析师评级
JP摩根维持对eyepoint pharmaceuticals的超配评级,将目标价下调至29美元。
摩根大通维持EyePoint Pharmaceuticals(EYPT.US)买入评级,下调目标价至29美元
分析师就医疗保健公司提供见解:eyepoint pharmaceuticals (EYPT),sarepta therapeutics (SRPT)和intra-cellular therapies (ITCI)
在有希望的DURAVYU试验前景中,眼点制药表现出买入乐观的评级
买入评级得到eyepoint pharmaceuticals强大的财务和有前途的DURAVYU试验的支撑
Duravyu的疗效和安全剖面有所提高,使得甲状腺药物eyepoint pharmaceuticals受到买入评级的推崇。
Chardan Capital维持对eyepoint pharmaceuticals的买入评级,维持目标价28美元。